Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAK-259 is a novel, selective, and orally active α1D adrenergic receptor antagonist (α1D, Ki = 1.1 nM) that represents a promising new therapeutic agent for the treatment of symptoms of OAB. It has an anti-frequency effect and reduces the burden of the human Ether-a-Go-Go-Related gene (HERG).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,670.00 | |
50 mg | 6-8 weeks | $ 2,180.00 | |
100 mg | 6-8 weeks | $ 2,800.00 |
Description | TAK-259 is a novel, selective, and orally active α1D adrenergic receptor antagonist (α1D, Ki = 1.1 nM) that represents a promising new therapeutic agent for the treatment of symptoms of OAB. It has an anti-frequency effect and reduces the burden of the human Ether-a-Go-Go-Related gene (HERG). |
Synonyms | TAK-259, TAK259 |
Molecular Weight | 410.7 |
Formula | C14H14Cl3N3O3S |
CAS No. | 1192347-42-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TAK-259 HCl 1192347-42-4 TAK 259 HCl TAK 259 TAK-259 TAK259 TAK259 HCl inhibitor inhibit